Hangzhou Xanda Medical Technology has focused on pharmaceutical data since 2005 — 21 years with the industry. Structured databases, mobile lookup and custom research help manufacturers, research groups and investors lock facts for portfolio, registration, access and competitor questions.
We connect isolated sources: data should do more than display results — it should help teams unpick risk, test assumptions and form the next move.
Global and China targets, clinical progress and FTO — to screen high-value small-molecule, biologic and improved-new-drug candidates.
Example — Dotinurad tablets: DrugSEA brings together the reference product (batch 93), 38 Class 4 chemical filings, 51 BE records and a 2030 compound-patent line, then outputs a three-probability portfolio view.
Different scenes, depths and frequencies: a desktop platform, a WeChat lookup, and custom research — as one service.
China and global registration, marketed, clinical and sales databases. Combined filters, multi-dimensional linkage and natural-language search.
A mobile intelligence entry for approvals, tenders/VBP, sales, registration review, clinical trials and subscriptions.
Built on the Xanda Drug Express monthly framework: portfolio due diligence, competitor sales and commercial-value studies that can be checked.
DrugSEA offers high-dimensional professional search, plus natural-language Q&A and a workspace that can generate charts and code-level artifacts.
db.drugsea.cn/search — DrugSEA professional
agent.drugsea.cn — DrugSEA natural-language workspace
The live V4 product: six mobile entries for approvals, tenders/VBP, sales, registration review and clinical trials.
Look up by INN, company or approval number; filter NRDL/EDL status.
From one approval to the label, filings, tender history and partnering companies.
Subscribe by acceptance number, company or product; WeChat push when status changes.
Hospital-sample and all-channel annual sales; compare forms of the same product.
Beyond the platforms, Xanda advisory delivers custom work: exclusive monthlies, portfolio models and quarterly market models for strategy.
A structured monthly from official CDE/NMPA public data: acceptances, new filings, approvals, generic consistency and Class 1 innovative drugs.
A three-probability frame: P1 approvability (87), P2 lawful launch now (18 — compound patent to 2030), P3 worth doing (47). Sequence capacity; do not sprint blindly.
All-channel annuals, hospital seasonality and log-trend calibration — same-prescription-family (tablet/granule/capsule) and near-indication brands across 31 provinces.
The filings below are current. Regulators, partners and clients can verify the certificates.
DrugSEA Enterprise, inFocus for teams, or a custom portfolio / competitor-sales study — an advisor will propose a fit.